ANTIMICROBIAL THERAPY OF PATIENTS WITH FAN-ASSOCIATED PNEUMONIA: FOCUS ON DOPIRENEM
https://doi.org/10.21518/2079-701X-2016-15-46-51
Abstract
The fan-associated pneumonia currently is a leading reason of mortality of patients in resuscitation and intensive care unit. Development of the disease is accompanied by serious clinical and economic consequences. The adequate antibacterial therapy plays the determining role in the favorable outcome in pneumonia. Doripemen is a new parenteral 1-beta-methyl-carbapenem that was launched into the pharmaceutical market of Russia in 2008.
The purpose of this review is to generalize the results accumulated to this moment on effectiveness of doripenem in therapy of fan-associated pneumonia.
About the Author
O. V. FESENKO
Russian Medical Academy of Postgraduate Education
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Чучалин А.Г., Гельфанд Б.Р. Нозокомиальная пневмония у взрослых: Российские национальные рекомендации. М., Компания Боргес, 2009, 90 стр.
2. Kalil А, Metersky M, Klompas M et al. Management of adults with hospital-acquired and Ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis, 2016, 63(5): 575-582.
3. Суворова М.П., Яковлев С.В., Басин Е.Е и соавт. Современные рекомендации по антибактериальной терапии нозокомиальной пневмонии в ОРИТ на основании многоцентрового мониторинга возбудителей и резистентности в лечебно-профилактических учреждениях России. Фарматека, 2015, 14(307): 46-50.
4. Wang Y, Eldridge N, Metersky ML, et al. National trends in patient safety for four common conditions, 2005–2011. N Engl J Med, 2014, 370: 341-51.
5. Heyland DK, Cook DJ, Grifith L et al., The attributable morbidity and mortality of ventilatorassociated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med, 1999, 159(4 Pt 1): 1249-56.
6. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis, 2013, 13: 665-71.
7. Muscedere JG, Day A, Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis, 2010, 51(suppl 1): 120-5.
8. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol, 2012, 33: 250-6.
9. Livermore DM. Doripenem: antimicrobial profile and clinical potential . Diagn. Microbiol. Infect. Dis., 2009, 63: 455-458.
10. Петухова И.Н., Дмитриева Н.В. Роль дорипенема в лечении тяжелых госпитальных инфекций. Эффективная фармакотерапия. Онкология, гематология и радиология, 2014, 2(37): 5-15.
11. Fritsche T.R., Sader H.S., Stillwell M.G., Jones R.N. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007). Diagn. Microbiol. Infect. Dis., 2009, 63(4): 440446.
12. Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю. и соавт. Антибиотикорезис тентность нозокомиальных штаммов Enterobacteriaceae в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011-2012 гг. Клин Микробиол Антимикроб Химиотер., 2014, 16(4): 254-265.
13. Mendes RE, Rhomberg PR, Bell JM et al. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagn. Microbiol. Infect. Dis., 2009, 63: 415-425.
14. Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю. и соавт. Антибиотикорезистентность нозокомиальных штаммов Pseudomonas aeruginosa в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011-2012 гг. Клин Микробиол Антимикроб Химиотер., 2014, 16(4): 273-279.
15. Сastanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn. Microbiol. Infect. Dis., 2009, 63(4): 426-433.
16. Gales AC, Azevedo HD, Cereda RF et al. Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITAA-DORI Brazilian study. Braz. J. Infect. Dis., 2011, 15(6): 513-520.
17. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother., 2004, 48(8): 3086-3092.
18. Fujimura T, Anan N, Sugimori G et al. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Int. J. Antimicrob. Agents., 2009, 34(6) : 523-528.
19. Sakyo S, Tomita H, Tanimoto K et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J. Antibiot. (Tokyo), 2006, 59(4): 220-228.
20. Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю. и соавт. Антибиотикорезис тентность нозокомиальных штаммов Acinetobacter spp. в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011-2012 гг. Клин Микробиол Антимикроб Химиотер., 2014, 16(4): 266-272.
21. Dong SX, Wang JT, Chang SC. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan. Microbiol. Immunol. Infection., 2012, 45: 59-464.
22. Somily AM, Absar MM, Arshad MZ et al. Antimicrobial susceptibility patterns of multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline. Saudi Med. J., 2012, 33(7): 750-755.
23. Marti S, Sanchez-Cespedes J, Alba V, Vila J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Int. J. Antimicrob. Agents, 2009, 33(2): 181-182.
24. Белоусов Ю.Б., Зырянов С.К., Штейнберг Л.Л. Карбапенемы (имипенем, меропенем, дорипенем) в лечении нозокомиальной пневмонии: современное состояние проблемы. Фарматека, 2011, 15(228): 16-23.
25. Rea-Neto A, Niederman M, Lobo SM et al. Efficacy and safety of doripenem versus piperacillin/ tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin, 2008, 24(7): 2113-26.
26. Chastre J, Wunderink R, Prokocimer P et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med, 2008, 36(4): 1089-96.
27. Mustafa M, Chan WM, Lee C еt al. A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study). Int. J. Antimicrob. Agents, 2014, 43(4): 353-360.
28. Jenkins SG, Fisher AC, Peterson JA, Nicholson SC, Kaniga K. Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Curr Med Res Opin, 2009 Dec, 25(12): 3029-36.
29. Qu XY, Hu TT, Zhou W. A meta-analysis of efficacy and safety of doripenem for treating bacterial infections. Braz J Infect Dis, 2015 Mar-Apr, 19(2): 156-62.
30. Merchant S, Gast C, Nathwani D et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther, 2008, 30(4): 717-33.
31. McGarry LJ, Merchant S, Nathwani D et al. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J Med Econ, 2010, 13(1): 142.
32. Kongnakorn T, Mwamburi M, Merchant S et al. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Curr Med Res Opin, 2010, 26(1): 17-24.
33. Белоусов Ю.Б., Зырянов С.К., Штейнберг Л.Л. Фармакоэкономические аспекты применения различных карбапенемов (имипенем/циластатин, меропенем, дорипенем) в лечении нозокомиальной пневмонии. Земский врач, 2013, 1: 15-20.
Review
For citations:
FESENKO OV. ANTIMICROBIAL THERAPY OF PATIENTS WITH FAN-ASSOCIATED PNEUMONIA: FOCUS ON DOPIRENEM. Meditsinskiy sovet = Medical Council. 2016;(15):46-51. (In Russ.) https://doi.org/10.21518/2079-701X-2016-15-46-51
Views:
552
Email this article 